middle.news
OncoSil Medical Joins European Consortium with Cost-Saving PULSE Trial in Pancreatic Cancer
8:46am on Thursday 2nd of July, 2026 AEST
•
Healthcare
Read Story
OncoSil Medical Joins European Consortium with Cost-Saving PULSE Trial in Pancreatic Cancer
8:46am on Thursday 2nd of July, 2026 AEST
Key Points
Selected for PALACROS consortium in Europe
PULSE Phase II trial evaluates repeat OncoSil™ treatment
Trial covers 120 patients across five centres
In-kind device provision saves approximately $9 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE